Short answer
Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026, with corporate update announced May 5, 2026.
Disc Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026, with corporate update announced May 5, 2026
- Full financial results and management commentary contained in Exhibit 99.1
- Investor focus: quarterly performance and updated corporate priorities disclosed in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss $63.5M, up from $34.1M, reflecting accelerated investment across the clinical pipeline
- Cash, equivalents, and marketable securities $730.2M, supporting operations into 2029 despite $60.99M quarterly cash decline from December
- Phase 3 APOLLO enrollment completed at 183 patients, with bitopertin topline EPP data expected Q4 2026
- FDA Type A meeting scheduled Q2 2026, with potential bitopertin resubmission response and FDA decision targeted for mid-2027
- Multiple catalysts concentrated in Q4 2026, including DISC-0974 topline MF data and DISC-3405 data in PV and SCD
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Disc Medicine, Inc. 8-K filings
Get the next IRON 8-K as it lands
Follow IRON for push alerts, or ask the research agent what this filing means.